ACLS · Axcelis Technologies, Inc.

The thesis

Axcelis Technologies has no company-specific case today, and the third-quarter report on 5 November 2026 is the first event that can build one. The adjusted close was $100.07 on 30 October 2026, below the $105 invalidation level in the previous note and 47.8% below the $191.6 52-week high. China's undated ruling on the Veeco merger is the second event that settles the case.

The decline has run without a company event. The adjusted close was $147.77 on 2 October 2026 and $111.21 on 19 October 2026. The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, stood at 27.8 on 30 October 2026. The shares are down 28.4% over three months.

The narrative is maturing: the Veeco merger and the chip-equipment recovery are well known, and the only new company facts since 8 September 2026 are the Korea groundbreaking on 20 October 2026 and a chief financial officer (CFO) change announced 27 October 2026. The shares are more likely to keep moving with semiconductor equipment peers than to lead the S&P 500 before the report.

Bullish and bearish views on Axcelis Technologies, Inc.

The bull case on Axcelis Technologies, Inc. (ACLS), in brief: Guidance points to sequential growth. The bear case: The price has broken lower without a rebound.

Bull case

• Guidance points to sequential growth. The company guided third-quarter 2026 revenue to approximately $230 million and non-GAAP earnings per share (EPS) to approximately $1.11 (Form 8-K, 6 August 2026). The second quarter delivered $215.2 million and $1.06.
• Revenue grew year over year. Second-quarter revenue was $215.2 million, up 10.6% from $194.5 million (Form 8-K exhibit, 6 August 2026). Service revenue rose 32.0% to $14.7 million.
• Selling is stretched to the downside. RSI(14) was 27.8 on 30 October 2026, against 92.3 on 2 October 2026. A confirmed report date gives the shares a dated test of whether guidance holds.

• Korea capacity is under construction. Axcelis began construction on 20 October 2026 of the $35 million Pyeongtaek ion implantation plant announced 8 September 2026, with production planned for the second half of 2028.

Bear case

• The price has broken lower without a rebound. The adjusted close of $100.07 on 30 October 2026 compares with $111.21 on 19 October 2026 and $115.08 on 4 September 2026. The shares sit below the 18 September 2026 close of $109.32 that preceded the autumn rally.
• Margins and earnings are falling. Second-quarter non-GAAP gross margin was 42.7%, against 45.2% a year earlier. GAAP diluted EPS was $0.75, against $0.98 (Form 8-K exhibit, 6 August 2026).
• China regulatory risk is unresolved. MLex reported on 10 July 2026 that the simplified filing with China's State Administration for Market Regulation (SAMR) was withdrawn after third-party complaints and moved to normal review. No ruling has been published, and the company's second-half 2026 closing target ends on 31 December 2026.
• Finance leadership changes before the report. Axcelis announced on 27 October 2026 that Jeroen Delsman becomes executive vice president and CFO effective 12 November 2026, succeeding David Ryzhik. The change takes effect one week after the third-quarter report.
• Valuation anchors sit near or below the price. GuruFocus put its GF Value estimate at $90.94 on 12 October 2026. BofA Securities kept an Underperform rating with a $156 target on 23 June 2026.

Price setup

The adjusted close was $100.07 on 30 October 2026, with RSI(14) at 27.8 and a three-month change of -28.4%. The shares gave back the whole autumn rally: the early-October close of $147.77 on 2 October 2026 is the high of that move, and the 18 September 2026 close of $109.32 that preceded it is now above the price.

The next reference points are the GuruFocus GF Value estimate of $90.94 and the round $100 level the shares closed just above on 30 October 2026. The $191.6 52-week high is 47.8% above the last close.

Crowding evidence is thin on the buying side. Simply Wall St reported a 14.30% weekly drop to $118.61 on 15 October 2026 with no named trigger. The imminent earnings date is the one crowding factor that can be observed: the report arrives within a week of the last close.

Catalysts, next 30 days

• 12 November 2026: Jeroen Delsman takes over as CFO (company announcement, 27 October 2026). The first call under the new CFO would follow the fourth-quarter report.
• Undated: SAMR ruling on the Veeco merger. The merger outside date auto-extends up to 30 June 2027 if regulatory approval is the only open condition, and the company targets a close by 31 December 2026.

Elapsed catalysts

• 5 November 2026: Third-quarter 2026 results before the market open, with the call at 8:30 a.m. ET (Axcelis announcement, 21 October 2026). Revenue against the approximately $230 million guidance, and gross margin against 42.7%, are the tests. (passed 1d ago)

What would change the view

The case breaks if third-quarter 2026 revenue comes in below the approximately $230 million guidance, if non-GAAP gross margin falls below the second quarter's 42.7%, or if the fourth-quarter outlook is weaker. A company filing disclosing termination of the Veeco merger, a SAMR prohibition, or a remedy-conditioned clearance would also end it.

On price, a daily close below $90, under the GuruFocus GF Value estimate of $90.94 from 12 October 2026, would end the case. A report that meets guidance with gross margin above 42.7%, together with a published SAMR clearance, would show a company-specific case forming.

What it trades with

Axcelis trades with semiconductor equipment peers, and the October decline came with no company filing. The merger is all-stock at 0.3575 Axcelis shares per Veeco share, so Veeco shares move with Axcelis shares and both reprice on a SAMR clearance or termination. China is both the merger gatekeeper and a large end market for the company's equipment.